{
    "Systemic Therapy for Advanced or Metastatic Disease (Continued)": {
        "PD-L1 Expression Positive (>=1%)": {
            "Pembrolizumab": "Progression (See NSCL-20)",
            "Atezolizumab": "Progression (See NSCL-20)",
            "Cemiplimab": "Progression (See NSCL-20)"
        },
        "PD-L1 Expression Negative (<1%)": {
            "Chemotherapy + Immunotherapy": "Progression (See NSCL-20)",
            "Chemotherapy": "Progression (See NSCL-20)"
        }
    },
    "footnotes": {
        "1": "See Principles of Systemic Therapy (NSCL-F)."
    }
}